Nociscan cost-effectiveness summary highlights dominance over provocative discography and might save the US healthcare system $283M to $441M yearly.
The Worldwide Society for the Development of Backbone Surgical procedure (ISASS) Annual Assembly was held June 1-3, 2023.
ISASS Coverage Assertion on Lumbar Spinal Fusion Surgical procedure acknowledges MR Spectroscopy as an efficient different to provocative discography.
BROOMFIELD, CO, June 08, 2023 (GLOBE NEWSWIRE) — by way of NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the placement of continual low again ache, introduced at this time their Nociscan cost-effectiveness summary was offered on the Worldwide Society for the Development of Backbone Surgical procedure on Saturday, June 3, 2023. The associated fee-effectiveness examine evaluating Nociscan to provocative discography was carried out on the Middle for Disruptive Musculoskeletal Improvements (CDMI) by way of a Nationwide Science Basis (NSF) grant sponsored by Aclarion. The summary highlights that Nociscan statistically dominates provocative discography (PD) as a result of PD is each extra expensive and fewer efficient.
“An evidence-based course of for correct identification of a supply for low again ache is effective to enhance cost-effectiveness of operative and non-operative administration methods,” stated Leslie Wilson, PhD, Professor within the Division of Medication and the Division of Medical Pharmacy at College of California San Francisco. “The financial mannequin features a decision-tree evaluating Nociscan with PD primarily based on a complete set of peer-reviewed knowledge. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan statistically dominates PD, with a Monte Carlo sensitivity evaluation illustrating Nociscan dominates over a large willingness-to-pay vary. In complete, Nociscan can save the US healthcare system from $283M to $441M yearly.”
Persistent low again ache (cLBP) is a world healthcare drawback, with roughly 266 million folks worldwide affected by degenerative spine illness and low again ache. Standard imaging and diagnostics present priceless structural info however battle to establish the supply of the pathogenic ache. Low surgical success charges (41-57%)1,2 are widespread particularly for sufferers affected by Discogenic Persistent Low Again Ache (DCLP).
“We’re happy with the cost-effectiveness summary outcomes,” stated Ryan Bond, Chief Technique Officer at Aclarion. “We imagine the outcomes illustrating Nociscan’s outperformance over provocative discography will likely be necessary to our doctor prospects and their sufferers, however may also communicate clearly to the payer group, who’re consistently challenged to reconcile the well being outcomes achieved for the {dollars} they spend; the worth in healthcare.”
Aclarion will likely be attending the American Society for Ache & Neuroscience (ASPN), July 13-16, 2023 in Miami, FL the place their well being economics outcomes Summary will likely be highlighted. For details about ASPN 2023, please go to: https://aspnpain.com/aspn-annual-conference-july-2023/
- Wei J, Music Y, et al. Comparability of synthetic complete disc substitute versus fusion for lumbar disc illness: a meta-anaylsis of randomized managed trials. Int Orthop. 2013; 37(7):1315-1325
- Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical remedy of continual low again ache: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers vital insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Ahead Trying Statements
This press launch incorporates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic information, similar to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to numerous uncertainties and dangers that might considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Alternate Fee. Readers are inspired to evaluation the part titled “Danger Components” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post